Chengdu Easton Biopharmaceuticals Co (SHSE:688513) EV-to-Revenue : 4.77 (As of May. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Chengdu Easton Biopharmaceuticals Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Chengdu Easton Biopharmaceuticals Co's enterprise value is ¥5,510 Mil. Chengdu Easton Biopharmaceuticals Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,154 Mil. Therefore, Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue for today is 4.77.

The historical rank and industry rank for Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue or its related term are showing as below:

SHSE:688513' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.37 Med: 4.42 Max: 6.02
Current: 4.77

During the past 8 years, the highest EV-to-Revenue of Chengdu Easton Biopharmaceuticals Co was 6.02. The lowest was 3.37. And the median was 4.42.

SHSE:688513's EV-to-Revenue is ranked better than
63.43% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs SHSE:688513: 4.77

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Chengdu Easton Biopharmaceuticals Co's stock price is ¥56.57. Chengdu Easton Biopharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥9.64. Therefore, Chengdu Easton Biopharmaceuticals Co's PS Ratio for today is 5.87.

Chengdu Easton Biopharmaceuticals Co EV-to-Revenue Historical Data

The historical data trend for Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Easton Biopharmaceuticals Co EV-to-Revenue Chart

Chengdu Easton Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

4.48

4.00

5.18

5.69

Chengdu Easton Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															4.37	4.65	4.80	5.69	4.84

Competitive Comparison of Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue

For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue falls into.

Chengdu Easton Biopharmaceuticals Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	5509.506	/	1154.258
	=	4.77

Chengdu Easton Biopharmaceuticals Co's current Enterprise Value is ¥5,510 Mil.
Chengdu Easton Biopharmaceuticals Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,154 Mil.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Chengdu Easton Biopharmaceuticals Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	56.57	/	9.639
	=	5.87

Chengdu Easton Biopharmaceuticals Co's share price for today is ¥56.57.
Chengdu Easton Biopharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥9.64.

Chengdu Easton Biopharmaceuticals Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chengdu Easton Biopharmaceuticals Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Easton Biopharmaceuticals Co Ltd (SHSE:688513) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731

Website

http://www.eastonpharma.cn

Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Headlines

No Headlines